Home Compare DXCM vs PODD
Stock Comparison · Industry comparison · Medical Devices

DexCom vs Insulet: Which Stock Looks Stronger in 2026?

DexCom holds the cleaner structural position, with valuation as the main driver and profitability adding further support. Insulet does not offset that deficit through any equally strong structural edge elsewhere. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The lead is spread across valuation and profitability, rather than sitting in one isolated gap. The overall score gap is 19 points in favour of DexCom, Inc..

INDUSTRY COMPARISON

Both operate in: Medical Devices

This comparison is based on industry proximity, not on functional trajectory similarity. DXCM and PODD share the same industry classification.

For a similarity-based comparison, see how DexCom and Insulet each position within their functional peer groups in AssetNext.

Peer-Relative Score
DXCM
DexCom, Inc.
69
Peer-Score
Signal qualityHigh
vs
PODD
Insulet Corporation
50
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Pricing and operating quality both support the lead here.

Dimension spread: DXCM vs PODD Profitability 97 73 Stability 14 18 Valuation 69 29 Growth 83 78 DXCM PODD
Gap Ranking
#1 Valuation +40
#2 Profitability +24
#3 Growth +5
#4 Stability +4
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for DXCM and PODD Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer DXCMPODD Relative valuation Structural strength

DexCom, Inc. looks stronger on relative valuation, while the broader price setup remains mixed.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Valuation
On valuation, DexCom, Inc. ranks near the top of the group; Insulet Corporation sits in the weaker half.
Profitability
On profitability, the edge still sits with DexCom, Inc., even though both profiles look solid.
Valuation — Dominant Gap
DXCM
69
PODD
29
Gap+40in favour of DXCM

The multiple-based pricing edge comes from a forward P/E that is 4.3 turns lower.

What else supports the lead

Profitability gives the lead a second hard layer of support, with a 7-point operating margin advantage.

What this means for the comparison

Valuation is the clearest driver, and profitability also supports DexCom, Inc.'s broader structural position.

Explore full peer positioning in AssetNext

Break down the DXCM vs PODD comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar valuation-and-profitability comparisons

Explore how DXCM and PODD each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.